142 related articles for article (PubMed ID: 18021470)
1. Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12.
Wysocka M; Newton S; Benoit BM; Introcaso C; Hancock AS; Chehimi J; Richardson SK; Gelfand JM; Montaner LJ; Rook AH
Clin Lymphoma Myeloma; 2007 Sep; 7(8):524-34. PubMed ID: 18021470
[TBL] [Abstract][Full Text] [Related]
2. Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-γ: implications for therapy of cutaneous T-cell lymphoma.
Wysocka M; Dawany N; Benoit B; Kossenkov AV; Troxel AB; Gelfand JM; Sell MK; Showe LC; Rook AH
Leuk Lymphoma; 2011 Oct; 52(10):1970-9. PubMed ID: 21942329
[TBL] [Abstract][Full Text] [Related]
3. The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients.
Kelly-Sell MJ; Kim YH; Straus S; Benoit B; Harrison C; Sutherland K; Armstrong R; Weng WK; Showe LC; Wysocka M; Rook AH
Am J Hematol; 2012 Apr; 87(4):354-60. PubMed ID: 22367792
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15.
Wysocka M; Benoit BM; Newton S; Azzoni L; Montaner LJ; Rook AH
Blood; 2004 Dec; 104(13):4142-9. PubMed ID: 15328153
[TBL] [Abstract][Full Text] [Related]
5. Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphoma.
Zaki MH; Wysocka M; Everetts SE; Wang KS; French LE; Ritz J; Rook AH
J Invest Dermatol; 2002 Feb; 118(2):366-71. PubMed ID: 11841558
[TBL] [Abstract][Full Text] [Related]
6. Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists.
Gorski KS; Waller EL; Bjornton-Severson J; Hanten JA; Riter CL; Kieper WC; Gorden KB; Miller JS; Vasilakos JP; Tomai MA; Alkan SS
Int Immunol; 2006 Jul; 18(7):1115-26. PubMed ID: 16728430
[TBL] [Abstract][Full Text] [Related]
7. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity.
Yoo EK; Cassin M; Lessin SR; Rook AH
J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181
[TBL] [Abstract][Full Text] [Related]
8. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production.
Hart OM; Athie-Morales V; O'Connor GM; Gardiner CM
J Immunol; 2005 Aug; 175(3):1636-42. PubMed ID: 16034103
[TBL] [Abstract][Full Text] [Related]
9. Sézary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines.
Wysocka M; Zaki MH; French LE; Chehimi J; Shapiro M; Everetts SE; McGinnis KS; Montaner L; Rook AH
Blood; 2002 Nov; 100(9):3287-94. PubMed ID: 12384429
[TBL] [Abstract][Full Text] [Related]
10. IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sézary syndrome.
Yoon JS; Newton SM; Wysocka M; Troxel AB; Hess SD; Richardson SK; Lin JH; Benoit BM; Kasprzycka M; Wasik MA; Rook AH
J Invest Dermatol; 2008 Feb; 128(2):473-80. PubMed ID: 17713571
[TBL] [Abstract][Full Text] [Related]
11. Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells.
Vowels BR; Cassin M; Vonderheid EC; Rook AH
J Invest Dermatol; 1992 Jul; 99(1):90-4. PubMed ID: 1607682
[TBL] [Abstract][Full Text] [Related]
12. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
[TBL] [Abstract][Full Text] [Related]
13. Increased interleukin 5 production in eosinophilic Sézary syndrome: regulation by interferon alfa and interleukin 12.
Suchin KR; Cassin M; Gottleib SL; Sood S; Cucchiara AJ; Vonderheid EC; Rook AH
J Am Acad Dermatol; 2001 Jan; 44(1):28-32. PubMed ID: 11148473
[TBL] [Abstract][Full Text] [Related]
14. TLR8 agonist partially improves IFN-γ deficiency of NK cells in chronic hepatitis B through the synergy of monocytes.
Ao X; Gan Q; Huang X; Bao D; Wu X; Lin Q; Lin A; Ding Y; Wang L; Chen Y; Huang Z
Aliment Pharmacol Ther; 2023 Feb; 57(4):387-398. PubMed ID: 36585909
[TBL] [Abstract][Full Text] [Related]
15. Human dendritic cells stimulated via TLR7 and/or TLR8 induce the sequential production of Il-10, IFN-gamma, and IL-17A by naive CD4+ T cells.
Lombardi V; Van Overtvelt L; Horiot S; Moingeon P
J Immunol; 2009 Mar; 182(6):3372-9. PubMed ID: 19265114
[TBL] [Abstract][Full Text] [Related]
16. Accessory-cell-mediated activation of porcine NK cells by toll-like receptor 7 (TLR7) and TLR8 agonists.
Toka FN; Nfon CK; Dawson H; Golde WT
Clin Vaccine Immunol; 2009 Jun; 16(6):866-78. PubMed ID: 19369481
[TBL] [Abstract][Full Text] [Related]
17. Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12.
Girart MV; Fuertes MB; Domaica CI; Rossi LE; Zwirner NW
J Immunol; 2007 Sep; 179(6):3472-9. PubMed ID: 17804388
[TBL] [Abstract][Full Text] [Related]
18. Activation of Human γδ T Cells: Modulation by Toll-Like Receptor 8 Ligands and Role of Monocytes.
Serrano R; Wesch D; Kabelitz D
Cells; 2020 Mar; 9(3):. PubMed ID: 32183240
[TBL] [Abstract][Full Text] [Related]
19. IL-12 reverses cytokine and immune abnormalities in Sezary syndrome.
Rook AH; Kubin M; Cassin M; Vonderheid EC; Vowels BR; Wolfe JT; Wolf SF; Singh A; Trinchieri G; Lessin SR
J Immunol; 1995 Feb; 154(3):1491-8. PubMed ID: 7822812
[TBL] [Abstract][Full Text] [Related]
20. TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity.
Du J; Wu Z; Ren S; Wei Y; Gao M; Randolph GJ; Qu C
Vaccine; 2010 Aug; 28(38):6273-81. PubMed ID: 20637759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
